vs
Amphastar Pharmaceuticals, Inc.（AMPH）与Apellis Pharmaceuticals, Inc.（APLS）财务数据对比。点击上方公司名可切换其他公司
Apellis Pharmaceuticals, Inc.的季度营收约是Amphastar Pharmaceuticals, Inc.的1.1倍（$199.9M vs $183.1M），Amphastar Pharmaceuticals, Inc.净利率更高（13.3% vs -29.5%，领先42.8%），Amphastar Pharmaceuticals, Inc.同比增速更快（-1.8% vs -5.9%），Amphastar Pharmaceuticals, Inc.自由现金流更多（$24.6M vs $-14.3M），过去两年Apellis Pharmaceuticals, Inc.的营收复合增速更高（7.7% vs 3.2%）
安福斯制药是一家上市的美国特种制药企业，公司成立于2004年5月，核心业务为吸入制剂及鼻腔给药产品的研发、生产与销售，聚焦特色医药领域深耕发展。
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
AMPH vs APLS — 直观对比
营收规模更大
APLS
是对方的1.1倍
$183.1M
营收增速更快
AMPH
高出4.1%
-5.9%
净利率更高
AMPH
高出42.8%
-29.5%
自由现金流更多
AMPH
多$38.9M
$-14.3M
两年增速更快
APLS
近两年复合增速
3.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $183.1M | $199.9M |
| 净利润 | $24.4M | $-59.0M |
| 毛利率 | 46.8% | — |
| 营业利润率 | 19.4% | -25.6% |
| 净利率 | 13.3% | -29.5% |
| 营收同比 | -1.8% | -5.9% |
| 净利润同比 | -35.7% | -62.2% |
| 每股收益（稀释后） | $0.51 | $-0.40 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMPHAPLS
| Q4 25 | $183.1M | $199.9M | ||
| Q3 25 | $191.8M | $458.6M | ||
| Q2 25 | $174.4M | $178.5M | ||
| Q1 25 | $170.5M | $166.8M | ||
| Q4 24 | $186.5M | $212.5M | ||
| Q3 24 | $191.2M | $196.8M | ||
| Q2 24 | $182.4M | $199.7M | ||
| Q1 24 | $171.8M | $172.3M |
净利润AMPHAPLS
| Q4 25 | $24.4M | $-59.0M | ||
| Q3 25 | $17.4M | $215.7M | ||
| Q2 25 | $31.0M | $-42.2M | ||
| Q1 25 | $25.3M | $-92.2M | ||
| Q4 24 | $38.0M | $-36.4M | ||
| Q3 24 | $40.4M | $-57.4M | ||
| Q2 24 | $37.9M | $-37.7M | ||
| Q1 24 | $43.2M | $-66.4M |
毛利率AMPHAPLS
| Q4 25 | 46.8% | — | ||
| Q3 25 | 51.4% | — | ||
| Q2 25 | 49.6% | — | ||
| Q1 25 | 50.0% | — | ||
| Q4 24 | 46.5% | — | ||
| Q3 24 | 53.3% | — | ||
| Q2 24 | 52.2% | — | ||
| Q1 24 | 52.4% | — |
营业利润率AMPHAPLS
| Q4 25 | 19.4% | -25.6% | ||
| Q3 25 | 13.2% | 48.7% | ||
| Q2 25 | 24.2% | -18.6% | ||
| Q1 25 | 21.9% | -50.0% | ||
| Q4 24 | 24.2% | -12.3% | ||
| Q3 24 | 29.8% | -24.0% | ||
| Q2 24 | 30.3% | -14.7% | ||
| Q1 24 | 27.9% | -36.0% |
净利率AMPHAPLS
| Q4 25 | 13.3% | -29.5% | ||
| Q3 25 | 9.0% | 47.0% | ||
| Q2 25 | 17.8% | -23.6% | ||
| Q1 25 | 14.8% | -55.3% | ||
| Q4 24 | 20.4% | -17.1% | ||
| Q3 24 | 21.1% | -29.2% | ||
| Q2 24 | 20.8% | -18.9% | ||
| Q1 24 | 25.1% | -38.5% |
每股收益（稀释后）AMPHAPLS
| Q4 25 | $0.51 | $-0.40 | ||
| Q3 25 | $0.37 | $1.67 | ||
| Q2 25 | $0.64 | $-0.33 | ||
| Q1 25 | $0.51 | $-0.74 | ||
| Q4 24 | $0.74 | $-0.30 | ||
| Q3 24 | $0.78 | $-0.46 | ||
| Q2 24 | $0.73 | $-0.30 | ||
| Q1 24 | $0.81 | $-0.54 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $282.8M | $466.2M |
| 总债务越低越好 | $608.7M | — |
| 股东权益账面价值 | $788.8M | $370.1M |
| 总资产 | $1.6B | $1.1B |
| 负债/权益比越低杠杆越低 | 0.77× | — |
8季度趋势，按日历期对齐
现金及短期投资AMPHAPLS
| Q4 25 | $282.8M | $466.2M | ||
| Q3 25 | $276.2M | $479.2M | ||
| Q2 25 | $231.8M | $370.0M | ||
| Q1 25 | $236.9M | $358.4M | ||
| Q4 24 | $221.6M | $411.3M | ||
| Q3 24 | $250.5M | $396.9M | ||
| Q2 24 | $217.8M | $360.1M | ||
| Q1 24 | $289.6M | $325.9M |
总债务AMPHAPLS
| Q4 25 | $608.7M | — | ||
| Q3 25 | $608.6M | — | ||
| Q2 25 | $607.7M | — | ||
| Q1 25 | $603.9M | — | ||
| Q4 24 | $601.6M | — | ||
| Q3 24 | $596.4M | — | ||
| Q2 24 | $586.9M | — | ||
| Q1 24 | $594.0M | $93.1M |
股东权益AMPHAPLS
| Q4 25 | $788.8M | $370.1M | ||
| Q3 25 | $776.7M | $401.2M | ||
| Q2 25 | $757.5M | $156.3M | ||
| Q1 25 | $751.3M | $164.2M | ||
| Q4 24 | $732.3M | $228.5M | ||
| Q3 24 | $727.7M | $237.1M | ||
| Q2 24 | $713.3M | $264.3M | ||
| Q1 24 | $672.4M | $266.7M |
总资产AMPHAPLS
| Q4 25 | $1.6B | $1.1B | ||
| Q3 25 | $1.7B | $1.1B | ||
| Q2 25 | $1.6B | $821.4M | ||
| Q1 25 | $1.6B | $807.3M | ||
| Q4 24 | $1.6B | $885.1M | ||
| Q3 24 | $1.5B | $901.9M | ||
| Q2 24 | $1.5B | $904.5M | ||
| Q1 24 | $1.6B | $831.9M |
负债/权益比AMPHAPLS
| Q4 25 | 0.77× | — | ||
| Q3 25 | 0.78× | — | ||
| Q2 25 | 0.80× | — | ||
| Q1 25 | 0.80× | — | ||
| Q4 24 | 0.82× | — | ||
| Q3 24 | 0.82× | — | ||
| Q2 24 | 0.82× | — | ||
| Q1 24 | 0.88× | 0.35× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $32.9M | $-14.2M |
| 自由现金流经营现金流 - 资本支出 | $24.6M | $-14.3M |
| 自由现金流率自由现金流/营收 | 13.4% | -7.1% |
| 资本支出强度资本支出/营收 | 4.5% | 0.1% |
| 现金转化率经营现金流/净利润 | 1.35× | — |
| 过去12个月自由现金流最近4个季度 | $121.2M | $45.0M |
8季度趋势，按日历期对齐
经营现金流AMPHAPLS
| Q4 25 | $32.9M | $-14.2M | ||
| Q3 25 | $52.6M | $108.5M | ||
| Q2 25 | $35.6M | $4.4M | ||
| Q1 25 | $35.1M | $-53.4M | ||
| Q4 24 | $29.0M | $19.4M | ||
| Q3 24 | $60.0M | $34.1M | ||
| Q2 24 | $69.1M | $-8.3M | ||
| Q1 24 | $55.3M | $-133.0M |
自由现金流AMPHAPLS
| Q4 25 | $24.6M | $-14.3M | ||
| Q3 25 | $47.2M | $108.3M | ||
| Q2 25 | $25.0M | $4.4M | ||
| Q1 25 | $24.4M | $-53.4M | ||
| Q4 24 | $16.6M | $19.3M | ||
| Q3 24 | $46.2M | — | ||
| Q2 24 | $63.1M | $-8.4M | ||
| Q1 24 | $46.5M | $-133.3M |
自由现金流率AMPHAPLS
| Q4 25 | 13.4% | -7.1% | ||
| Q3 25 | 24.6% | 23.6% | ||
| Q2 25 | 14.3% | 2.5% | ||
| Q1 25 | 14.3% | -32.0% | ||
| Q4 24 | 8.9% | 9.1% | ||
| Q3 24 | 24.1% | — | ||
| Q2 24 | 34.6% | -4.2% | ||
| Q1 24 | 27.1% | -77.3% |
资本支出强度AMPHAPLS
| Q4 25 | 4.5% | 0.1% | ||
| Q3 25 | 2.8% | 0.0% | ||
| Q2 25 | 6.1% | 0.0% | ||
| Q1 25 | 6.3% | 0.0% | ||
| Q4 24 | 6.7% | 0.0% | ||
| Q3 24 | 7.2% | 0.0% | ||
| Q2 24 | 3.3% | 0.0% | ||
| Q1 24 | 5.1% | 0.2% |
现金转化率AMPHAPLS
| Q4 25 | 1.35× | — | ||
| Q3 25 | 3.03× | 0.50× | ||
| Q2 25 | 1.15× | — | ||
| Q1 25 | 1.39× | — | ||
| Q4 24 | 0.76× | — | ||
| Q3 24 | 1.48× | — | ||
| Q2 24 | 1.82× | — | ||
| Q1 24 | 1.28× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
